Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders (Q36310235)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders (English)

1 reference

Europe PubMed Central

13 August 2017

2

object named as

Rainer Storb

1 reference

Europe PubMed Central

13 August 2017

author name string

Frédéric Baron

1

1 reference

Europe PubMed Central

13 August 2017

publication date

8 November 2005

1 reference

Europe PubMed Central

13 August 2017

Molecular Therapy

1 reference

Europe PubMed Central

13 August 2017

13

1 reference

Europe PubMed Central

13 August 2017

1

1 reference

Europe PubMed Central

13 August 2017

26-41

1 reference

Europe PubMed Central

13 August 2017

Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-leukemia reactions in allogeneic chimeras

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

The role of allogeneic transplantation in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Transplantation of X-linked severe combined immunodeficient dogs with CD34+ bone marrow cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

What role is there for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Mixed chimerism: preclinical studies and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Mixed bone marrow chimerism as a treatment for autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Severe canine hereditary hemolytic anemia treated by nonmyeloablative marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Specific suppressor cells in graft-host tolerance of HLA-identical marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-host disease: how to translate new insights into new therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Stem cell gene transfer--efficacy and safety in large animal studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Molecules and mechanisms of the graft-versus-leukaemia effect

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Genetic modification of T lymphocytes for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Identifiers

10.1016/J.YMTHE.2005.09.011

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36310235&oldid=1625172169"